The Upcoming
  • Culture
    • Art
    • Cinema & Tv
      • Movie reviews
      • Film festivals
      • Shows
    • Food & Drinks
      • News & Features
      • Restaurant & bar reviews
      • Interviews & Recipes
    • Literature
    • Music
      • Live music
    • Theatre
  • Fashion & Lifestyle
    • Accessories
    • Beauty
    • News & Features
    • Shopping & Trends
    • Tips & How-tos
    • Fashion weeks
  • What’s On
    • Art exhibitions
    • Theatre shows
  • Tickets
  • Join us
    • Editorial unit
    • Our writers
    • Join the team
    • Join the mailing list
    • Support us
    • Contact us
  • Interviews
  • Competitions
  • Special events
    • Film festivals
      • Berlin
      • Tribeca
      • Sundance London
      • Cannes
      • Locarno
      • Venice
      • London
      • Toronto
    • Fashion weeks
      • London Fashion Week
      • New York Fashion Week
      • Milan Fashion Week
      • Paris Fashion Week
      • Haute Couture
      • London Fashion Week Men’s
  • Facebook

  • Twitter

  • Instagram

  • YouTube

  • RSS

Current affairsNewsScience, Health & Technology

Breast cancer drug turned down for NHS deemed too expensive

Breast cancer drug turned down for NHS deemed too expensive
23 April 2014
Samantha Waite
Avatar
Samantha Waite
23 April 2014

A breast cancer drug that can prolong life by nearly six months has been deemed too expensive and turned down for the NHS.

The drug, called Kadcyla (generic name trastuzumab emtansine), costs approximately £90,000 per patient but offers to extend life by almost six months.

The National Institute for Health and Care Excellence (NICE), which sets the guidelines for England and Wales, believes that the drug is not effective enough to support the large sum.

The watchdog is consulting the manufacturer Roche to reduce its’ costs and give NHS patients free access to it.

NICE justified the decision, telling the Guardian “the reality is that given its price and what it offers to patients, it will displace more health benefits, which the NHS could achieve in other ways, than it will offer to patients with breast cancer.”

The decision has been heavily criticised by both breast cancer charities and Roche.

Speaking to the Huffington Post, chief executive of NICE Sir Andrew Dillon said: “Roche would act in the best interest of patients and use the consultation period to look again at their evidence and consider if there was more they could do.”

The drug is available in England via the government’s Cancer Drugs Fund (CDF). But the scheme will soon end in 2016 and patients in England will no longer be able to get Kadcyla through the NHS.

Although, Kadcyla isn’t a cure, it prolongs life by a median of 5.8 months. The drug combines Herceptin (trastuzamab) with a chemotherapy agent and is a new medicine for those with HER 2-positive secondary breast cancer and has fewer side effects than other drugs.

Studies show that Kadcyla has a survival rate of 30.9 months compared with 25.1 months for patients on lapatinib and capecitabine.

Professor Paul Ellis, a consultant oncologist at King’s College London, who worked on the drug trials said: “Kadcyla represents a significant advance in HER 2-positive breast cancer, so for NICE to issue negative preliminary guidance is a huge blow.”

Back in 2010, NICE rejected another breast cancer drug Lapatinib, also known as Tyverb, on the basis of costs, which is now widely used and highly successful with cancer patients.

Samantha Waite

Related ItemsBreast cancercancercancer drugmedicine

More in Current Affairs

Changes to expect during menopause

The editorial unit
Read More

Nek brings Italian pop rock to the Shepherd’s Bush Empire

The editorial unit
Read More

Why Equity Linked Savings Schemes is a preferred tax saving?

The editorial unit
Read More

How the world’s top designers would rebrand political parties

The editorial unit
Read More

Royal baby furore: Proof that the British monarchy is still popular?

Eoin O’Sullivan-Harris
Read More

World Mental Health Day 2018: Raising awareness and combating stigma

The editorial unit
Read More

Seven political personalities you should know about

The editorial unit
Read More

Donald Trump: An enemy of the arts?

The editorial unit
Read More

Trump’s fortune: Where did the money come from?

The editorial unit
Read More
Scroll for more
Tap
  • Popular

  • Latest

  • TOP PICKS

  • Creation Stories
    ★★★★★
    Film festivals
  • Detroit Stories – Alice Cooper
    ★★★★★
    Album review
  • Judas and the Black Messiah
    ★★★★★
    Movie review
  • Gatsby at Cadogan Hall: An interview with Jodie Steele and Ross William Wild
    Theatre
  • Laura Mvula – Under a Pink Moon
    ★★★★★
    Live music
  • Mr Bachmann and His Class (Herr Bachmann und Seine Klasse)
    ★★★★★
    Berlinale
  • Tides
    ★★★★★
    Berlinale
  • Back to the Wharf
    ★★★★★
    Film festivals
  • Ted K
    Berlinale
  • Nebenan (Next Door)
    ★★★★★
    Berlinale
  • We (Nous)
    ★★★★★
    Berlinale
  • Bicep at Saatchi Gallery Online
    ★★★★★
    Live music
  • The Winter Lake
    ★★★★★
    Movie review
  • Spotlight: Lauren Everet and Soup Kitchen London, striving for food security and social equality
    Food & Drinks
  • Da Capo
    ★★★★★
    Film festivals
The Upcoming
Pages
  • Contact us
  • Join mailing list
  • Join us
  • Our London food map
  • Our writers
  • Support us
  • What, when, why

Copyright © 2011-2020 FL Media

New family justice reforms introduced in England and Wales
Dying cancer patient raises £1million after bidding farewell on Facebook